Lucemyra (lofexidine)

Indications for Prior Authorization

Lucemyra (lofexidine)
  • For diagnosis of Opioid withdrawal
    Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Criteria

Lucemyra

Step Therapy

Length of Approval: 12 Month(s)

  • Requested drug is being used for a Food and Drug Administration (FDA)-approved indication
  • AND
  • Trial and failure (of a minimum 30-day supply), contraindication, or intolerance to clonidine
P & T Revisions

2024-01-03, 2023-01-04, 2022-01-06, 2021-01-06, 2020-01-17

  1. Lucemyra Prescribing Information. USWM, LLC. Louisville, KY. September 2020.

  • 2024-01-03: Annual review: No updates required.
  • 2023-01-04: Annual review: Updated criteria.
  • 2022-01-06: Annual review: Updated criteria and background.
  • 2021-01-06: Annual review: No updates required.
  • 2020-01-17: Annual review: no updates required.

Happy New Year! If you are calling our Member Services department today, we ask for your patience while our entire team assists members with their questions. The first week in January is always the busiest time of year and we will get to your call as soon as possible. Members may find the information you need by logging into our secure MyWHA member portal. Use the "log in" button at the top right of this homepage screen. Thank you. Contact Us